JP2023548046A5 - - Google Patents
Info
- Publication number
- JP2023548046A5 JP2023548046A5 JP2023524629A JP2023524629A JP2023548046A5 JP 2023548046 A5 JP2023548046 A5 JP 2023548046A5 JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023548046 A5 JP2023548046 A5 JP 2023548046A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- complement
- patient
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105018P | 2020-10-23 | 2020-10-23 | |
| US63/105,018 | 2020-10-23 | ||
| PCT/US2021/056153 WO2022087339A1 (en) | 2020-10-23 | 2021-10-22 | Methods of treating patients having complement disorders using anti-c5 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548046A JP2023548046A (ja) | 2023-11-15 |
| JP2023548046A5 true JP2023548046A5 (enExample) | 2024-10-29 |
Family
ID=78695818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524629A Pending JP2023548046A (ja) | 2020-10-23 | 2021-10-22 | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240018220A1 (enExample) |
| EP (1) | EP4232473A1 (enExample) |
| JP (1) | JP2023548046A (enExample) |
| CA (1) | CA3196434A1 (enExample) |
| WO (1) | WO2022087339A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| JP7518764B2 (ja) | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| WO2026101219A1 (ko) * | 2024-11-06 | 2026-05-15 | 주식회사 이뮨앱스 | 보체 c5 결합 단백질 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| TWI828672B (zh) * | 2017-01-31 | 2024-01-11 | 日商中外製藥股份有限公司 | 用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法 |
| JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| AU2018383751B2 (en) * | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
-
2021
- 2021-10-22 EP EP21810811.6A patent/EP4232473A1/en active Pending
- 2021-10-22 CA CA3196434A patent/CA3196434A1/en active Pending
- 2021-10-22 US US18/032,959 patent/US20240018220A1/en active Pending
- 2021-10-22 WO PCT/US2021/056153 patent/WO2022087339A1/en not_active Ceased
- 2021-10-22 JP JP2023524629A patent/JP2023548046A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7227312B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| TWI660972B (zh) | 抗ｍｃａｍ抗體及相關使用方法 | |
| JP6262715B2 (ja) | ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用 | |
| TW201934581A (zh) | 抗ｂ７－ｈ４抗體、其抗原結合片段及其醫藥用途 | |
| JP2018501813A5 (enExample) | ||
| JP7461875B2 (ja) | 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| TWI869542B (zh) | 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途 | |
| JP2023548046A (ja) | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 | |
| TWI836070B (zh) | 抗trop-2抗體、其抗原結合片段及其醫藥用途 | |
| BR112021005276A2 (pt) | anticorpos anti-cd45rc humanos e usos dos mesmos | |
| AU2011336702A1 (en) | Neoantibodies for diagnosing tissue injury | |
| TW202144433A (zh) | 抗體或其抗原結合片段、其製備方法及醫藥用途 | |
| TW202547857A (zh) | 抗ｈａｓ抗體及其組合物 | |
| US20260139047A1 (en) | Pharmaceutical composition containing fusion protein | |
| WO2024245388A1 (zh) | 抗pvrig抗体及其应用 | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| JP6143209B1 (ja) | 自己免疫疾患用または難治性血管炎用の治療剤、および、これらの疾患の診断のためのデータの取得方法 | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof |